“…Recently, attention has turned to the development of pharmacological compounds designed to target Rev-erb and ROR nuclear receptors within the circadian mechanism, offering potential clinical applications [ [36] , [37] , [38] ] [ [36] , [37] , [38] ] [ [36] , [37] , [38] ]. The administration of Rev-erbα agonists to mice has shown promise in treating metabolic disorders and improving inflammatory processing [ [39] , [40] , [41] ] [ [39] , [40] , [41] ] [ [39] , [40] , [41] ]. Additionally, various micro-RNAs have been identified that target Bmal1 to regulate circadian rhythms [ [42] , [43] , [44] ] [ [42] , [43] , [44] ] [ [42] , [43] , [44] ].…”